PARP inhibitors have been labelled as one of the biggest breakthough for medicine and oncology. myChoice CDx tumour testing, allows for the precise selection of patients likely to benefit from PARP inhibitors.  Comprising of a composite score of Loss of Heterozygosity (LOH), Telomeric Allelic Imbalance (TAI), and Large-scale State Transitions (LST) – using DNA isolated from tumour tissue.

The results of this test are used as an aid in identifying patient with ovarian, prostate and pancreas cancers who are positive for homologous recombination deficiency (HRD) and likely to benefit from PARP inhibitors.